Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27722979 | 0.83 | KDM4E (0.40) | RIPK1 | |
| SCHEMBL15166116 | 0.83 | KDM4E (0.37) | — | |
| SCHEMBL26511727 | 0.83 | GPR119 (0.49) | — | |
| SCHEMBL29169081 | 0.82 | GPR119 (0.43) | CYP3A4PARP1 | |
| Hydrochloric Acid SCHEMBL29169184 | 0.81 | GPR119 (0.43) | CYP3A4PARP1 | |
| SCHEMBL16761846 | 0.80 | KDM4E (0.56) | — | |
| SCHEMBL1103994 | 0.79 | GPR119 (0.43) | — | |
| SCHEMBL13666598 | 0.78 | RIPK1 (0.44) | RIPK1CYP3A4SIGMAR1DRD2 | |
| SCHEMBL23117948 | 0.78 | MAPT (0.46) | — | |
| SCHEMBL20064015 | 0.77 | SIGMAR1 (0.45) | RIPK1CYP3A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854678-B | RIPK1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116854678-A | RIPK1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-112370452-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-107624111-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-110913858-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-101657471-B | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP | 2013-07-03 | — | — | CN | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101657471-A | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP US | 2010-02-24 | — | — | CN | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | RIPK1 2851/4885CYP3A4 570/4885SIGMAR1 3676/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | RIPK1 2851/4885CYP3A4 570/4885SIGMAR1 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.